nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—MTOR—cervical cancer	0.713	1	CbGaD
Sirolimus—ABCB1—Topotecan—cervical cancer	0.0537	0.625	CbGbCtD
Sirolimus—CYP3A4—Topotecan—cervical cancer	0.0322	0.375	CbGbCtD
Sirolimus—EIF4E—uterine cervix—cervical cancer	0.00419	0.0567	CbGeAlD
Sirolimus—EIF4E—renal system—cervical cancer	0.00392	0.0531	CbGeAlD
Sirolimus—EIF4E—uterus—cervical cancer	0.00349	0.0473	CbGeAlD
Sirolimus—EIF4E—female reproductive system—cervical cancer	0.00314	0.0425	CbGeAlD
Sirolimus—FGF2—uterine cervix—cervical cancer	0.00255	0.0346	CbGeAlD
Sirolimus—Everolimus—MTOR—cervical cancer	0.00246	0.306	CrCbGaD
Sirolimus—Pimecrolimus—MTOR—cervical cancer	0.00246	0.306	CrCbGaD
Sirolimus—FGF2—decidua—cervical cancer	0.00243	0.033	CbGeAlD
Sirolimus—FGF2—endometrium—cervical cancer	0.00231	0.0313	CbGeAlD
Sirolimus—FGF2—mammalian vulva—cervical cancer	0.00223	0.0303	CbGeAlD
Sirolimus—FGF2—uterus—cervical cancer	0.00213	0.0288	CbGeAlD
Sirolimus—FGF2—female gonad—cervical cancer	0.00174	0.0236	CbGeAlD
Sirolimus—FGF2—vagina—cervical cancer	0.00173	0.0234	CbGeAlD
Sirolimus—Temsirolimus—MTOR—cervical cancer	0.00166	0.207	CrCbGaD
Sirolimus—Pelvic pain—Topotecan—cervical cancer	0.00164	0.0438	CcSEcCtD
Sirolimus—MTOR—epithelium—cervical cancer	0.00163	0.0221	CbGeAlD
Sirolimus—MTOR—renal system—cervical cancer	0.00152	0.0205	CbGeAlD
Sirolimus—FKBP1A—epithelium—cervical cancer	0.00147	0.0199	CbGeAlD
Sirolimus—MTOR—endometrium—cervical cancer	0.00147	0.0199	CbGeAlD
Sirolimus—Tacrolimus—MTOR—cervical cancer	0.00146	0.182	CrCbGaD
Sirolimus—FKBP1A—uterine cervix—cervical cancer	0.00146	0.0197	CbGeAlD
Sirolimus—MTOR—mammalian vulva—cervical cancer	0.00142	0.0192	CbGeAlD
Sirolimus—Interstitial lung disease—Topotecan—cervical cancer	0.00141	0.0376	CcSEcCtD
Sirolimus—FKBP1A—decidua—cervical cancer	0.00139	0.0188	CbGeAlD
Sirolimus—FKBP1A—renal system—cervical cancer	0.00136	0.0185	CbGeAlD
Sirolimus—MTOR—uterus—cervical cancer	0.00135	0.0183	CbGeAlD
Sirolimus—FKBP1A—endometrium—cervical cancer	0.00132	0.0179	CbGeAlD
Sirolimus—Pleural effusion—Topotecan—cervical cancer	0.0013	0.0348	CcSEcCtD
Sirolimus—FKBP1A—mammalian vulva—cervical cancer	0.00128	0.0173	CbGeAlD
Sirolimus—SLC47A1—uterine cervix—cervical cancer	0.00125	0.017	CbGeAlD
Sirolimus—FKBP1A—uterus—cervical cancer	0.00122	0.0165	CbGeAlD
Sirolimus—MTOR—female reproductive system—cervical cancer	0.00121	0.0164	CbGeAlD
Sirolimus—SLC47A1—decidua—cervical cancer	0.00119	0.0162	CbGeAlD
Sirolimus—SLC47A1—renal system—cervical cancer	0.00117	0.0159	CbGeAlD
Sirolimus—SLCO1B1—renal system—cervical cancer	0.00116	0.0157	CbGeAlD
Sirolimus—SLC47A1—endometrium—cervical cancer	0.00113	0.0153	CbGeAlD
Sirolimus—FGF2—lymph node—cervical cancer	0.00112	0.0152	CbGeAlD
Sirolimus—MTOR—female gonad—cervical cancer	0.00111	0.015	CbGeAlD
Sirolimus—MTOR—vagina—cervical cancer	0.0011	0.0149	CbGeAlD
Sirolimus—Hyperbilirubinaemia—Topotecan—cervical cancer	0.0011	0.0293	CcSEcCtD
Sirolimus—SLC47A1—mammalian vulva—cervical cancer	0.0011	0.0148	CbGeAlD
Sirolimus—FKBP1A—female reproductive system—cervical cancer	0.00109	0.0148	CbGeAlD
Sirolimus—SLC47A1—uterus—cervical cancer	0.00104	0.0141	CbGeAlD
Sirolimus—Bone pain—Topotecan—cervical cancer	0.00104	0.0278	CcSEcCtD
Sirolimus—Pulmonary embolism—Topotecan—cervical cancer	0.000999	0.0266	CcSEcCtD
Sirolimus—FKBP1A—female gonad—cervical cancer	0.000994	0.0135	CbGeAlD
Sirolimus—FKBP1A—vagina—cervical cancer	0.000988	0.0134	CbGeAlD
Sirolimus—SLC47A1—female reproductive system—cervical cancer	0.000939	0.0127	CbGeAlD
Sirolimus—Neuropathy—Topotecan—cervical cancer	0.000937	0.025	CcSEcCtD
Sirolimus—SLCO1B1—female reproductive system—cervical cancer	0.000927	0.0126	CbGeAlD
Sirolimus—Neoplasm—Topotecan—cervical cancer	0.000903	0.0241	CcSEcCtD
Sirolimus—Sepsis—Topotecan—cervical cancer	0.000866	0.0231	CcSEcCtD
Sirolimus—SLC47A1—female gonad—cervical cancer	0.000854	0.0116	CbGeAlD
Sirolimus—Ear pain—Topotecan—cervical cancer	0.00085	0.0227	CcSEcCtD
Sirolimus—SLC47A1—vagina—cervical cancer	0.000849	0.0115	CbGeAlD
Sirolimus—Anaphylactoid reaction—Topotecan—cervical cancer	0.000749	0.02	CcSEcCtD
Sirolimus—MTOR—lymph node—cervical cancer	0.00071	0.00962	CbGeAlD
Sirolimus—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.000653	0.0174	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Topotecan—cervical cancer	0.000639	0.0171	CcSEcCtD
Sirolimus—FKBP1A—lymph node—cervical cancer	0.000639	0.00865	CbGeAlD
Sirolimus—CYP3A5—uterine cervix—cervical cancer	0.000635	0.0086	CbGeAlD
Sirolimus—Pancytopenia—Topotecan—cervical cancer	0.000595	0.0159	CcSEcCtD
Sirolimus—CYP3A5—renal system—cervical cancer	0.000594	0.00804	CbGeAlD
Sirolimus—Neutropenia—Topotecan—cervical cancer	0.000586	0.0156	CcSEcCtD
Sirolimus—Weight increased—Topotecan—cervical cancer	0.00057	0.0152	CcSEcCtD
Sirolimus—Pneumonia—Topotecan—cervical cancer	0.000562	0.015	CcSEcCtD
Sirolimus—Infestation NOS—Topotecan—cervical cancer	0.000559	0.0149	CcSEcCtD
Sirolimus—Infestation—Topotecan—cervical cancer	0.000559	0.0149	CcSEcCtD
Sirolimus—SLC47A1—lymph node—cervical cancer	0.000549	0.00744	CbGeAlD
Sirolimus—Neuropathy peripheral—Topotecan—cervical cancer	0.000548	0.0146	CcSEcCtD
Sirolimus—Stomatitis—Topotecan—cervical cancer	0.000544	0.0145	CcSEcCtD
Sirolimus—Sweating—Topotecan—cervical cancer	0.000535	0.0143	CcSEcCtD
Sirolimus—Hepatobiliary disease—Topotecan—cervical cancer	0.000528	0.0141	CcSEcCtD
Sirolimus—Epistaxis—Topotecan—cervical cancer	0.000527	0.0141	CcSEcCtD
Sirolimus—Haemoglobin—Topotecan—cervical cancer	0.000504	0.0134	CcSEcCtD
Sirolimus—Rhinitis—Topotecan—cervical cancer	0.000503	0.0134	CcSEcCtD
Sirolimus—Haemorrhage—Topotecan—cervical cancer	0.000501	0.0134	CcSEcCtD
Sirolimus—Hypoaesthesia—Topotecan—cervical cancer	0.000499	0.0133	CcSEcCtD
Sirolimus—Pharyngitis—Topotecan—cervical cancer	0.000498	0.0133	CcSEcCtD
Sirolimus—Angiopathy—Topotecan—cervical cancer	0.000455	0.0121	CcSEcCtD
Sirolimus—Immune system disorder—Topotecan—cervical cancer	0.000453	0.0121	CcSEcCtD
Sirolimus—Mediastinal disorder—Topotecan—cervical cancer	0.000452	0.0121	CcSEcCtD
Sirolimus—Chills—Topotecan—cervical cancer	0.00045	0.012	CcSEcCtD
Sirolimus—CYP3A4—renal system—cervical cancer	0.000446	0.00604	CbGeAlD
Sirolimus—Malnutrition—Topotecan—cervical cancer	0.000437	0.0116	CcSEcCtD
Sirolimus—CYP3A5—female gonad—cervical cancer	0.000433	0.00586	CbGeAlD
Sirolimus—CYP3A5—vagina—cervical cancer	0.00043	0.00583	CbGeAlD
Sirolimus—Back pain—Topotecan—cervical cancer	0.000422	0.0113	CcSEcCtD
Sirolimus—Muscle spasms—Topotecan—cervical cancer	0.00042	0.0112	CcSEcCtD
Sirolimus—Ill-defined disorder—Topotecan—cervical cancer	0.000405	0.0108	CcSEcCtD
Sirolimus—Anaemia—Topotecan—cervical cancer	0.000403	0.0108	CcSEcCtD
Sirolimus—Angioedema—Topotecan—cervical cancer	0.000399	0.0106	CcSEcCtD
Sirolimus—Malaise—Topotecan—cervical cancer	0.000394	0.0105	CcSEcCtD
Sirolimus—Leukopenia—Topotecan—cervical cancer	0.000391	0.0104	CcSEcCtD
Sirolimus—Cough—Topotecan—cervical cancer	0.000381	0.0102	CcSEcCtD
Sirolimus—Chest pain—Topotecan—cervical cancer	0.000372	0.00992	CcSEcCtD
Sirolimus—Myalgia—Topotecan—cervical cancer	0.000372	0.00992	CcSEcCtD
Sirolimus—Arthralgia—Topotecan—cervical cancer	0.000372	0.00992	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000369	0.00985	CcSEcCtD
Sirolimus—Discomfort—Topotecan—cervical cancer	0.000367	0.0098	CcSEcCtD
Sirolimus—CYP3A4—female reproductive system—cervical cancer	0.000357	0.00483	CbGeAlD
Sirolimus—Anaphylactic shock—Topotecan—cervical cancer	0.000356	0.00951	CcSEcCtD
Sirolimus—Infection—Topotecan—cervical cancer	0.000354	0.00944	CcSEcCtD
Sirolimus—Nervous system disorder—Topotecan—cervical cancer	0.000349	0.00932	CcSEcCtD
Sirolimus—Thrombocytopenia—Topotecan—cervical cancer	0.000349	0.00931	CcSEcCtD
Sirolimus—Skin disorder—Topotecan—cervical cancer	0.000346	0.00923	CcSEcCtD
Sirolimus—Hyperhidrosis—Topotecan—cervical cancer	0.000344	0.00919	CcSEcCtD
Sirolimus—ABCB1—epithelium—cervical cancer	0.00034	0.00461	CbGeAlD
Sirolimus—Anorexia—Topotecan—cervical cancer	0.00034	0.00906	CcSEcCtD
Sirolimus—ABCB1—uterine cervix—cervical cancer	0.000337	0.00457	CbGeAlD
Sirolimus—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000325	0.00866	CcSEcCtD
Sirolimus—ABCB1—decidua—cervical cancer	0.000321	0.00435	CbGeAlD
Sirolimus—Paraesthesia—Topotecan—cervical cancer	0.00032	0.00854	CcSEcCtD
Sirolimus—Dyspnoea—Topotecan—cervical cancer	0.000318	0.00848	CcSEcCtD
Sirolimus—ABCB1—renal system—cervical cancer	0.000315	0.00427	CbGeAlD
Sirolimus—Dyspepsia—Topotecan—cervical cancer	0.000314	0.00837	CcSEcCtD
Sirolimus—Decreased appetite—Topotecan—cervical cancer	0.00031	0.00826	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Topotecan—cervical cancer	0.000308	0.00821	CcSEcCtD
Sirolimus—ABCB1—endometrium—cervical cancer	0.000305	0.00413	CbGeAlD
Sirolimus—Pain—Topotecan—cervical cancer	0.000305	0.00813	CcSEcCtD
Sirolimus—Constipation—Topotecan—cervical cancer	0.000305	0.00813	CcSEcCtD
Sirolimus—ABCB1—mammalian vulva—cervical cancer	0.000295	0.004	CbGeAlD
Sirolimus—Feeling abnormal—Topotecan—cervical cancer	0.000294	0.00783	CcSEcCtD
Sirolimus—Gastrointestinal pain—Topotecan—cervical cancer	0.000291	0.00777	CcSEcCtD
Sirolimus—Abdominal pain—Topotecan—cervical cancer	0.000282	0.00752	CcSEcCtD
Sirolimus—Body temperature increased—Topotecan—cervical cancer	0.000282	0.00752	CcSEcCtD
Sirolimus—ABCB1—uterus—cervical cancer	0.000281	0.00381	CbGeAlD
Sirolimus—Hypersensitivity—Topotecan—cervical cancer	0.000262	0.007	CcSEcCtD
Sirolimus—Asthenia—Topotecan—cervical cancer	0.000256	0.00682	CcSEcCtD
Sirolimus—ABCB1—female reproductive system—cervical cancer	0.000253	0.00342	CbGeAlD
Sirolimus—Pruritus—Topotecan—cervical cancer	0.000252	0.00673	CcSEcCtD
Sirolimus—Diarrhoea—Topotecan—cervical cancer	0.000244	0.0065	CcSEcCtD
Sirolimus—Dizziness—Topotecan—cervical cancer	0.000236	0.00629	CcSEcCtD
Sirolimus—ABCB1—female gonad—cervical cancer	0.00023	0.00311	CbGeAlD
Sirolimus—ABCB1—vagina—cervical cancer	0.000229	0.0031	CbGeAlD
Sirolimus—Vomiting—Topotecan—cervical cancer	0.000227	0.00604	CcSEcCtD
Sirolimus—Rash—Topotecan—cervical cancer	0.000225	0.00599	CcSEcCtD
Sirolimus—Dermatitis—Topotecan—cervical cancer	0.000224	0.00599	CcSEcCtD
Sirolimus—Headache—Topotecan—cervical cancer	0.000223	0.00596	CcSEcCtD
Sirolimus—Nausea—Topotecan—cervical cancer	0.000212	0.00565	CcSEcCtD
Sirolimus—ABCB1—lymph node—cervical cancer	0.000148	0.002	CbGeAlD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	9.55e-05	0.00117	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—TP53—cervical cancer	9.5e-05	0.00116	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—CTNNB1—cervical cancer	9.49e-05	0.00116	CbGpPWpGaD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—cervical cancer	9.49e-05	0.00116	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—STAT3—cervical cancer	9.47e-05	0.00116	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—MTOR—cervical cancer	9.46e-05	0.00115	CbGpPWpGaD
Sirolimus—FGF2—Immune System—UBE3A—cervical cancer	9.23e-05	0.00113	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HLA-DPB1—cervical cancer	9.09e-05	0.00111	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	9.05e-05	0.0011	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—NOTCH2—cervical cancer	8.92e-05	0.00109	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	8.91e-05	0.00109	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—STAT3—cervical cancer	8.9e-05	0.00109	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	8.84e-05	0.00108	CbGpPWpGaD
Sirolimus—FGF2—Disease—WNT2—cervical cancer	8.65e-05	0.00106	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—WNT5A—cervical cancer	8.65e-05	0.00106	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—EGFR—cervical cancer	8.61e-05	0.00105	CbGpPWpGaD
Sirolimus—MTOR—PI-3K cascade—EGFR—cervical cancer	8.55e-05	0.00104	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	8.52e-05	0.00104	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—STAT3—cervical cancer	8.52e-05	0.00104	CbGpPWpGaD
Sirolimus—MTOR—PI3K/AKT activation—EGFR—cervical cancer	8.34e-05	0.00102	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—EGFR—cervical cancer	8.28e-05	0.00101	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—WNT5A—cervical cancer	8.26e-05	0.00101	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—EGFR—cervical cancer	8.24e-05	0.00101	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—EGFR—cervical cancer	8.24e-05	0.00101	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—CASP3—cervical cancer	8.23e-05	0.001	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—EGFR—cervical cancer	8.11e-05	0.00099	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—cervical cancer	8.09e-05	0.000987	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—EGFR—cervical cancer	8.09e-05	0.000987	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—WNT2—cervical cancer	8e-05	0.000976	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HES1—cervical cancer	7.95e-05	0.00097	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—CTNNB1—cervical cancer	7.93e-05	0.000968	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—cervical cancer	7.92e-05	0.000967	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—STAT3—cervical cancer	7.9e-05	0.000964	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TAAR6—cervical cancer	7.76e-05	0.000948	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—EGFR—cervical cancer	7.74e-05	0.000945	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—HLA-DQB1—cervical cancer	7.74e-05	0.000945	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—STAT3—cervical cancer	7.72e-05	0.000943	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—EGFR—cervical cancer	7.7e-05	0.00094	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—EGFR—cervical cancer	7.67e-05	0.000936	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	7.63e-05	0.000932	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—EGFR—cervical cancer	7.63e-05	0.000931	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CASP8—cervical cancer	7.57e-05	0.000923	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—cervical cancer	7.52e-05	0.000918	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	7.48e-05	0.000913	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—FGFR3—cervical cancer	7.34e-05	0.000896	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD8A—cervical cancer	7.23e-05	0.000882	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—EGFR—cervical cancer	7.18e-05	0.000876	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	7.18e-05	0.000876	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—EGFR—cervical cancer	7.18e-05	0.000876	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—EGFR—cervical cancer	7.11e-05	0.000868	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HLA-DQB1—cervical cancer	7.1e-05	0.000866	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—EGFR—cervical cancer	7.05e-05	0.000861	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—STAT3—cervical cancer	7.03e-05	0.000858	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKAP13—cervical cancer	7.02e-05	0.000857	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—EGFR—cervical cancer	7.02e-05	0.000857	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	6.99e-05	0.000854	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—MTOR—cervical cancer	6.96e-05	0.00085	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—STAT3—cervical cancer	6.91e-05	0.000844	CbGpPWpGaD
Sirolimus—MTOR—Immune System—UBE3A—cervical cancer	6.85e-05	0.000836	CbGpPWpGaD
Sirolimus—FGF2—Extracellular matrix organization—CASP3—cervical cancer	6.83e-05	0.000833	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—cervical cancer	6.79e-05	0.000829	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	6.75e-05	0.000824	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-DPB1—cervical cancer	6.74e-05	0.000823	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—EGFR—cervical cancer	6.64e-05	0.000811	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD8A—cervical cancer	6.63e-05	0.000809	CbGpPWpGaD
Sirolimus—FGF2—Disease—WNT5A—cervical cancer	6.56e-05	0.000801	CbGpPWpGaD
Sirolimus—MTOR—Disease—WNT2—cervical cancer	6.42e-05	0.000784	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—CASP3—cervical cancer	6.4e-05	0.000781	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—EGFR—cervical cancer	6.39e-05	0.00078	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	6.36e-05	0.000776	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—STAT3—cervical cancer	6.32e-05	0.000772	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	6.29e-05	0.000768	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—cervical cancer	6.11e-05	0.000746	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—WNT5A—cervical cancer	6.06e-05	0.00074	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—WNT2—cervical cancer	6.06e-05	0.00074	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—cervical cancer	6.05e-05	0.000738	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—EGFR—cervical cancer	6.02e-05	0.000734	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—NOTCH1—cervical cancer	6e-05	0.000732	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—FGFR3—cervical cancer	5.91e-05	0.000722	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—STAT3—cervical cancer	5.86e-05	0.000715	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NOTCH2—cervical cancer	5.8e-05	0.000708	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TAAR6—cervical cancer	5.76e-05	0.000703	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—EGFR—cervical cancer	5.75e-05	0.000701	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—STAT3—cervical cancer	5.73e-05	0.0007	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—CASP3—cervical cancer	5.72e-05	0.000699	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—EGFR—cervical cancer	5.72e-05	0.000698	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	5.72e-05	0.000698	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—EGFR—cervical cancer	5.69e-05	0.000694	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	5.67e-05	0.000692	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—EGFR—cervical cancer	5.66e-05	0.000691	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—FGFR3—cervical cancer	5.64e-05	0.000689	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—cervical cancer	5.58e-05	0.000681	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—CTNNB1—cervical cancer	5.53e-05	0.000675	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—NOTCH1—cervical cancer	5.52e-05	0.000674	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-DPB1—cervical cancer	5.51e-05	0.000673	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—FGFR3—cervical cancer	5.42e-05	0.000661	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—STAT3—cervical cancer	5.38e-05	0.000657	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	5.33e-05	0.00065	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—EGFR—cervical cancer	5.33e-05	0.00065	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—EGFR—cervical cancer	5.33e-05	0.00065	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKAP13—cervical cancer	5.32e-05	0.000649	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—EGFR—cervical cancer	5.28e-05	0.000644	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HLA-DQB1—cervical cancer	5.27e-05	0.000643	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—cervical cancer	5.23e-05	0.000639	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—EGFR—cervical cancer	5.21e-05	0.000636	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	5.19e-05	0.000634	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—cervical cancer	5.08e-05	0.00062	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CASP8—cervical cancer	5.06e-05	0.000617	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HES1—cervical cancer	4.98e-05	0.000608	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—EGFR—cervical cancer	4.93e-05	0.000602	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD8A—cervical cancer	4.92e-05	0.0006	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—EGFR—cervical cancer	4.89e-05	0.000597	CbGpPWpGaD
Sirolimus—MTOR—Disease—WNT5A—cervical cancer	4.87e-05	0.000594	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CASP8—cervical cancer	4.83e-05	0.000589	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HES1—cervical cancer	4.75e-05	0.00058	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—CASP3—cervical cancer	4.75e-05	0.00058	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	4.72e-05	0.000576	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—WNT5A—cervical cancer	4.59e-05	0.000561	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—WNT2—cervical cancer	4.5e-05	0.000549	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MTHFR—cervical cancer	4.38e-05	0.000534	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CA9—cervical cancer	4.37e-05	0.000533	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TERT—cervical cancer	4.36e-05	0.000533	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HLA-DQB1—cervical cancer	4.3e-05	0.000525	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—STAT3—cervical cancer	4.26e-05	0.00052	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NOTCH2—cervical cancer	4.25e-05	0.000519	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—FGFR3—cervical cancer	4.19e-05	0.000511	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TERT—cervical cancer	4.17e-05	0.000509	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—MTOR—cervical cancer	4.16e-05	0.000508	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD4—cervical cancer	4.15e-05	0.000507	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-DPB1—cervical cancer	4.09e-05	0.000499	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—FGFR3—cervical cancer	4.02e-05	0.000491	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD8A—cervical cancer	4.02e-05	0.000491	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CA9—cervical cancer	4.01e-05	0.000489	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—FGFR3—cervical cancer	4e-05	0.000489	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—STAT3—cervical cancer	3.99e-05	0.000487	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—CTNNB1—cervical cancer	3.99e-05	0.000486	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—MTOR—cervical cancer	3.97e-05	0.000485	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CD4—cervical cancer	3.96e-05	0.000484	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKAP13—cervical cancer	3.95e-05	0.000482	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—FGFR3—cervical cancer	3.82e-05	0.000467	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—MTOR—cervical cancer	3.81e-05	0.000465	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD4—cervical cancer	3.81e-05	0.000464	CbGpPWpGaD
Sirolimus—FGF2—Disease—HES1—cervical cancer	3.77e-05	0.000461	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NOTCH1—cervical cancer	3.76e-05	0.000459	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	3.73e-05	0.000456	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CTNNB1—cervical cancer	3.69e-05	0.00045	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—cervical cancer	3.63e-05	0.000443	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NOTCH1—cervical cancer	3.59e-05	0.000438	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CASP8—cervical cancer	3.58e-05	0.000437	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CTNNB1—cervical cancer	3.52e-05	0.00043	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HES1—cervical cancer	3.49e-05	0.000426	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—STAT3—cervical cancer	3.47e-05	0.000424	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—WNT5A—cervical cancer	3.41e-05	0.000416	CbGpPWpGaD
Sirolimus—FGF2—Disease—MTHFR—cervical cancer	3.32e-05	0.000405	CbGpPWpGaD
Sirolimus—FGF2—Disease—TERT—cervical cancer	3.31e-05	0.000404	CbGpPWpGaD
Sirolimus—FGF2—Immune System—FGFR3—cervical cancer	3.29e-05	0.000401	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—cervical cancer	3.25e-05	0.000396	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOTCH2—cervical cancer	3.22e-05	0.000393	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—STAT3—cervical cancer	3.21e-05	0.000392	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HLA-DQB1—cervical cancer	3.19e-05	0.00039	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—cervical cancer	3.16e-05	0.000385	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TERT—cervical cancer	3.06e-05	0.000373	CbGpPWpGaD
Sirolimus—FGF2—Disease—FGFR3—cervical cancer	3.03e-05	0.00037	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD8A—cervical cancer	2.98e-05	0.000364	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CD4—cervical cancer	2.94e-05	0.000359	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—cervical cancer	2.92e-05	0.000357	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CA9—cervical cancer	2.9e-05	0.000354	CbGpPWpGaD
Sirolimus—FGF2—Disease—NOTCH1—cervical cancer	2.85e-05	0.000348	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	2.83e-05	0.000345	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD4—cervical cancer	2.82e-05	0.000345	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MTOR—cervical cancer	2.82e-05	0.000344	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CD4—cervical cancer	2.81e-05	0.000343	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CASP8—cervical cancer	2.81e-05	0.000343	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—FGFR3—cervical cancer	2.8e-05	0.000342	CbGpPWpGaD
Sirolimus—MTOR—Disease—HES1—cervical cancer	2.8e-05	0.000342	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—cervical cancer	2.79e-05	0.00034	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	2.72e-05	0.000332	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MTOR—cervical cancer	2.69e-05	0.000328	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—cervical cancer	2.68e-05	0.000327	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HES1—cervical cancer	2.64e-05	0.000323	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NOTCH1—cervical cancer	2.63e-05	0.000321	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CTNNB1—cervical cancer	2.61e-05	0.000319	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CTNNB1—cervical cancer	2.5e-05	0.000305	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CASP3—cervical cancer	2.47e-05	0.000302	CbGpPWpGaD
Sirolimus—MTOR—Disease—MTHFR—cervical cancer	2.46e-05	0.0003	CbGpPWpGaD
Sirolimus—MTOR—Disease—TERT—cervical cancer	2.45e-05	0.0003	CbGpPWpGaD
Sirolimus—MTOR—Immune System—FGFR3—cervical cancer	2.44e-05	0.000298	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH2—cervical cancer	2.39e-05	0.000292	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CTNNB1—cervical cancer	2.38e-05	0.000291	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TERT—cervical cancer	2.32e-05	0.000283	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MTOR—cervical cancer	2.31e-05	0.000282	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD4—cervical cancer	2.31e-05	0.000282	CbGpPWpGaD
Sirolimus—MTOR—Disease—FGFR3—cervical cancer	2.25e-05	0.000275	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CA9—cervical cancer	2.19e-05	0.000267	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—STAT3—cervical cancer	2.18e-05	0.000266	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	2.16e-05	0.000263	CbGpPWpGaD
Sirolimus—FGF2—Disease—MTOR—cervical cancer	2.13e-05	0.000261	CbGpPWpGaD
Sirolimus—FGF2—Disease—CD4—cervical cancer	2.13e-05	0.00026	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—FGFR3—cervical cancer	2.13e-05	0.000259	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOTCH1—cervical cancer	2.11e-05	0.000258	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CASP8—cervical cancer	2.09e-05	0.000255	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—STAT3—cervical cancer	2.08e-05	0.000254	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—cervical cancer	2.07e-05	0.000253	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CTNNB1—cervical cancer	2.05e-05	0.00025	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOTCH1—cervical cancer	2e-05	0.000244	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—cervical cancer	1.99e-05	0.000243	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—cervical cancer	1.98e-05	0.000242	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MTOR—cervical cancer	1.97e-05	0.000241	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HES1—cervical cancer	1.96e-05	0.000239	CbGpPWpGaD
Sirolimus—FGF2—Disease—CTNNB1—cervical cancer	1.89e-05	0.000231	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—cervical cancer	1.89e-05	0.000231	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP3—cervical cancer	1.81e-05	0.000221	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.81e-05	0.000221	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT3—cervical cancer	1.79e-05	0.000218	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MTHFR—cervical cancer	1.77e-05	0.000216	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—cervical cancer	1.75e-05	0.000213	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TERT—cervical cancer	1.72e-05	0.00021	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD4—cervical cancer	1.71e-05	0.000209	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—cervical cancer	1.65e-05	0.000201	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MTHFR—cervical cancer	1.63e-05	0.000199	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—cervical cancer	1.62e-05	0.000198	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—cervical cancer	1.59e-05	0.000194	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—cervical cancer	1.58e-05	0.000193	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—FGFR3—cervical cancer	1.58e-05	0.000193	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—cervical cancer	1.52e-05	0.000186	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—cervical cancer	1.52e-05	0.000186	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—cervical cancer	1.5e-05	0.000183	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MTOR—cervical cancer	1.5e-05	0.000182	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH1—cervical cancer	1.48e-05	0.000181	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—cervical cancer	1.4e-05	0.000171	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—cervical cancer	1.39e-05	0.000169	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—cervical cancer	1.38e-05	0.000168	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CA9—cervical cancer	1.35e-05	0.000164	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—cervical cancer	1.33e-05	0.000162	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—cervical cancer	1.33e-05	0.000162	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—cervical cancer	1.22e-05	0.000149	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—cervical cancer	1.21e-05	0.000147	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MTHFR—cervical cancer	1.18e-05	0.000144	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—cervical cancer	1.16e-05	0.000142	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—cervical cancer	1.16e-05	0.000141	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—cervical cancer	1.11e-05	0.000136	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—cervical cancer	1.05e-05	0.000128	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—cervical cancer	1.02e-05	0.000125	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—cervical cancer	9.84e-06	0.00012	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTHFR—cervical cancer	8.87e-06	0.000108	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—cervical cancer	8.82e-06	0.000108	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—cervical cancer	8.57e-06	0.000105	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—cervical cancer	7.79e-06	9.51e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—cervical cancer	6.54e-06	7.99e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTHFR—cervical cancer	5.47e-06	6.67e-05	CbGpPWpGaD
